Q5135
HCPCSInj, tyenne, 1 mg
Official HCPCS Level II long descriptor
Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
HCPCS Level II code Q5135 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Inj, tyenne, 1 mg
Added to HCPCS: 2024-10-01
Nearby codes in Q5
- Q5125Inj, releuko 1 mcg
- Q5126Inj alymsys 10 mg
- Q5127Inj, stimufend, 0.5 mg
- Q5128Inj, cimerli, 0.1 mg
- Q5129Inj, vegzelma, 10 mg
- Q5130Inj, fylnetra, 0.5 mg
- Q5133Inj, tofidence, 1 mg
- Q5134Inj, tyruko, 1 mg
- Q5136Inj. denosumab-bbdz, 1 mg
- Q5137Inj, wezlana, sub cu, 1 mg
- Q5138Inj, wezlana, iv, 1 mg
- Q5140Inj adalimumab-fkjp, 1 mg
- Q5141Inj adalimumab-aaty, 1 mg
- Q5142Inj adalimumab-ryvk, 1 mg
- Q5143Inj adalimumab-adbm, 1 mg
- Q5144Inj, idacio, 1 mg
Where this code sits
Krasyn AI Coder
Get code suggestions automatically as you type notes. Free for 50 analyses.
Install for Chrome — freeSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.